View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
April 17, 2020updated 12 Jul 2022 11:55am

Impact of Covid-19 pandemic on clinical trials evaluating various neurology indications

By GlobalData Healthcare

Covid-19 is an unprecedented event that has impacted nearly every aspect of businesses around the world, and while the pharma industry is being tapped to help bring out an effective treatment against the pandemic at the earliest, like others, the sector has also been subject to the brutal impact of the pandemic. Ongoing clinical trials are expected to face delays with disruptions to trial enrolment, data collection, and data analysis. The objective of this overview is to provide a brief synopsis of the impact of the pandemic on clinical trials evaluating various neurology indications.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

According to GlobalData’s Intelligence Center, a total of 81 trials with a definite neurology indication were identified as those impacted by the pandemic as of 15 April. Of these trials, indications related to pain and mental health are the most dominant, with the former accounting for 21% and the latter accounting for 19%. For the purpose of simplifying the representation, mental health indications here include those related to depression, psychiatric disorders, psychosis, schizophrenia, and other unspecified disorders. Clinical trials evaluating various forms of addiction such as those related to alcohol, opium, and nicotine also feature in the top three neurology indications, accounting for 11% of trials impacted by the crisis. A breakdown of these trials impacted by Covid-19 is shown in Figure 1.

The aforementioned dataset from GlobalData also reveals that of the trials that are impacted, 59% are sponsored by industry, while the remainder are driven by academic institutes. A combination of lockdown measures, as well as the need to re-prioritise existing healthcare resources in a hospital setting especially to focus on Covid-19 patients, are essential steps being taken in order to combat the virus. From an industry perspective, companies are needing to adapt their clinical trials in order to adhere to social distancing guidelines and to ensure that risks to clinical trial participants are minimised during such operations.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena